CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance

뉴스 본문을 불러오고 있어요.

CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance | 웨이프 WAPE

CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance

기사 요약

관련 종목

댓글 —